SP-15028

SP-15028 is a preclinical-stage drug candidate developed by Spherium Biomed for the treatment of muscle injury. Spherium Biomed, originally a joint venture between Ferrer and Janus Pharmaceuticals, focused on advancing early-stage biomedical projects from academic research into clinical development. SP-15028 was part of this portfolio, specifically targeting recovery or therapeutic intervention following muscle trauma. In 2018, Ferrer acquired full control of Spherium Biomed and integrated its pipeline. Detailed information regarding the molecular target, modality, and specific mechanism of action for SP-15028 remains proprietary and has not been disclosed in public clinical or pharmacological databases.